What Is 5-Amino-1MQ? The NNMT Inhibitor Research Compound Explained

5-Amino-1MQ NNMT inhibitor NAD salvage pathway methylation small molecule research compound Durham Peptides Canada

5-Amino-1MQ occupies an unusual corner of the Durham Peptides catalog — it's not a peptide. It's a small-molecule research compound, specifically a selective inhibitor of an enzyme called NNMT (nicotinamide N-methyltransferase). The reason it appears alongside the peptide catalog is its mechanistic overlap with NAD+ research: by inhibiting NNMT, 5-Amino-1MQ has been studied for its effects on NAD+ salvage pathway

preservation — the same metabolic axis NAD+ research targets, but from a completely different angle. This article walks through what 5-Amino-1MQ actually is, the NNMT mechanism, and how it relates to (but isn't part of) the peptide research category.

For Canadian researchers, Durham Peptides carries 5-Amino-1MQ 10mg. Nothing here is medical, dosing, or therapeutic guidance.

Important Framing: 5-Amino-1MQ Is Not a Peptide

The Durham Peptides catalog is built around research peptides (chains of amino acids), and the "≥99% purity, Janoshik-verified" framework is the standard those peptides are held to. 5-Amino-1MQ is a small molecule, not a peptide — chemically it's a pyridinium compound (5-amino-1-methylquinolinium iodide is the most common research form). It's included in the catalog as a research compound related to the NAD+ research category through its NNMT-inhibitor mechanism, but it's structurally and chemically different from the peptide products around it.

This distinction matters for a few reasons:

• Quality verification standards for small molecules can differ from peptides (though high-purity research-grade material remains the standard)

• The research literature comes from chemistry and metabolic-enzyme research, not peptide pharmacology

• The compound's behavior, stability, and handling differ from peptide products

So 5-Amino-1MQ is a research compound in the NAD+ research category, sold for research use only — just not a peptideresearch compound.

The Mechanism: NNMT Inhibition

The core research interest in 5-Amino-1MQ is its investigated inhibition of NNMT (nicotinamide N-methyltransferase)— an enzyme that uses S-adenosylmethionine (SAM) as a methyl donor to convert nicotinamide to 1-methylnicotinamide (1-MNA), which is then excreted.

Why this matters:

1. Nicotinamide is the salvage substrate for NAD+ biosynthesis. When the body recycles NAD+, nicotinamide is the intermediate that gets re-converted back into fresh NAD+ via the salvage pathway. Methylating nicotinamide and excreting it removes it from the salvage pool.

2. SAM is the universal methyl donor. Methylation reactions across the cell — DNA methylation, histone methylation, protein methylation — all depend on SAM. NNMT consumes SAM at potentially high rates when it's overactive.

So NNMT inhibition has been studied for two related metabolic consequences: preserving nicotinamide in the NAD+ salvage pool (potentially supporting NAD+ levels) and preserving SAM for other methylation reactions (potentially affecting broader methylation balance). The investigated NAD+ angle is what places 5-Amino-1MQ in the broader longevity/metabolic research category alongside NAD+ itself.

Research Area 1: NAD+ Salvage Pathway Preservation

The most-developed line of 5-Amino-1MQ research is its investigated effect on NAD+ salvage pathway activity. In animal models with elevated NNMT activity (which has been associated with various metabolic and aging-related conditions in research), NNMT inhibition has been studied for its effects on NAD+ levels, energy metabolism, and adipose tissue function.

This is the adjacent-pathway relationship to NAD+ research itself: where NAD+ is the coenzyme being supplemented directly, 5-Amino-1MQ is studied for preserving the body's own NAD+ recycling. The two compounds engage the NAD+ axis from opposite directions. See NAD+ vs NMN vs NR for the broader NAD-boosting compound comparison; 5-Amino-1MQ is a different mechanistic category from those direct precursors.

Research Area 2: Metabolic and Adipose Tissue Research

5-Amino-1MQ has been studied in metabolic models — particularly in adipose-tissue and energy-metabolism research. NNMT levels are elevated in some metabolic contexts, and inhibiting the enzyme has been investigated for its effects on adipocyte function, fat storage and mobilization research models, and metabolic markers in animal studies.

This places 5-Amino-1MQ adjacent to (but mechanistically distinct from) the broader metabolic research peptide category — including the GLP-1 peptides like semaglutide and the amylin-pathway compounds like CagriSema. 5-Amino-1MQ is an enzyme-inhibition mechanism, not a receptor-agonist mechanism.

Research Area 3: Methylation Balance

The SAM-preservation angle of NNMT inhibition has been studied in research contexts where methylation balancematters — epigenetic methylation, methylation-dependent signaling, and related areas. This is a less-developed research thread than the NAD+ side but reflects the dual mechanistic consequence of inhibiting an SAM-consuming enzyme.

What Researchers Examine

• NNMT enzyme inhibition kinetics and selectivity

• NAD+ levels and NAD+ salvage pathway flux in research models

• 1-Methylnicotinamide (1-MNA) excretion as a marker of NNMT activity

• Adipose-tissue and metabolic research outcomes

• SAM levels and methylation balance

• Comparison with direct NAD+ precursors (NMN, NR, NAD+ itself)

How 5-Amino-1MQ Fits the Longevity Research Map

5-Amino-1MQ adds a fifth mechanistic angle to the longevity research toolkit covered in The Best Longevity Peptides for Research in Canada:

• NAD+ → direct coenzyme supplementation

• MOTS-c → mitochondrial-derived peptide / AMPK signaling

• Epithalon → telomerase / telomere biology

• GHK-Cu → gene expression / collagen / skin aging

• 5-Amino-1MQ → NNMT inhibition / NAD+ salvage preservation / methylation balance

It's the only non-peptide in this map, and the only mechanism here that works by inhibiting an enzyme rather than by direct receptor or coenzyme action.

Quality and Storage

Durham Peptides' 5-Amino-1MQ is supplied as a research-grade compound. Storage: per the product page guidance, typically refrigerated and protected from light and moisture; reconstitute per the protocol of the research being conducted. See the product page for current batch and handling information.

Frequently Asked Questions

Is 5-Amino-1MQ a peptide? No — it's a small-molecule research compound (a pyridinium compound), not an amino-acid chain. It appears alongside the peptide catalog because of its mechanistic overlap with NAD+ research.

What does 5-Amino-1MQ do mechanistically? It's been studied as a selective inhibitor of NNMT (nicotinamide N-methyltransferase), with investigated effects on NAD+ salvage pathway flux and SAM-dependent methylation balance.

How is 5-Amino-1MQ different from NAD+? NAD+ is the coenzyme itself; 5-Amino-1MQ inhibits an enzyme (NNMT) that affects how the body recycles NAD+. Different mechanism, same metabolic axis.

What is 5-Amino-1MQ studied for? NNMT inhibition kinetics, NAD+ salvage pathway preservation, adipose-tissue and metabolic research, and methylation balance research.

Is 5-Amino-1MQ a NAD+ precursor like NMN or NR? No — it's a different mechanistic category entirely. NMN and NR are precursors that feed into NAD+ biosynthesis; 5-Amino-1MQ inhibits an enzyme that recycles nicotinamide out of the NAD+ pool.

Where can I buy 5-Amino-1MQ in Canada? Durham Peptides supplies 5-Amino-1MQ 10mg for laboratory use only.

Final Thoughts

5-Amino-1MQ is a mechanistically distinctive addition to the NAD+ and longevity research toolkit — a small-molecule NNMT inhibitor that approaches the NAD+ axis from the salvage-preservation angle rather than direct supplementation. Its position in the Durham Peptides catalog reflects research-relevance to the NAD+ category rather than peptide chemistry; it's a research compound studied in animal metabolic and longevity research models.

For the NAD+ side of the same axis, see What Is NAD+?; for the broader longevity-compound map, see The Best Longevity Peptides for Research in Canada; for NAD-precursor comparisons, see NAD+ vs NMN vs NR.

Selected Research References

1. Kraus D, Yang Q, Kong D, et al. Nicotinamide N-Methyltransferase Knockdown Protects Against Diet-Induced Obesity. Nature. 2014;508(7495):258-262. https://pubmed.ncbi.nlm.nih.gov/24717514/

2. Neelakantan H, Vance V, Wetzel MD, et al. Selective and Membrane-Permeable Small Molecule Inhibitors of Nicotinamide N-Methyltransferase Reverse High Fat Diet-Induced Obesity in Mice. Biochemical Pharmacology. 2018;147:141-152. https://pubmed.ncbi.nlm.nih.gov/29161520/

3. Pissios P. Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme. Trends in Endocrinology & Metabolism. 2017;28(5):340-353. https://pubmed.ncbi.nlm.nih.gov/28291578/

4. Hong S, Moreno-Navarrete JM, Wei X, et al. Nicotinamide N-Methyltransferase Regulates Hepatic Nutrient Metabolism through Sirt1 Protein Stabilization. Nature Medicine. 2015;21(8):887-894. https://pubmed.ncbi.nlm.nih.gov/26168293/

All products sold by Durham Peptides are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.